Sodium-glucose co-transporter-2 inhibitors and the risk of perioperative euglycaemic diabetic ketoacidosis

Link to article at PubMed

Br J Hosp Med (Lond). 2022 Nov 2;83(11):1-2. doi: 10.12968/hmed.2022.0398. Epub 2022 Nov 21.


Sodium-glucose co-transporter-2 inhibitors are increasingly prescribed for patients with type 2 diabetes. Their use has been associated with life-threatening diabetic ketoacidosis. The risk is increased during times of fasting and intercurrent medical illness, which are common in the perioperative period. Diagnosis can be difficult, so perioperative clinicians must be familiar with preventing and recognising such complications.

PMID:36454070 | DOI:10.12968/hmed.2022.0398

Leave a Reply

Your email address will not be published. Required fields are marked *